SAN FRANCISCO — In this Healio Video Perspective from Eyecelerator@AAO, Megan Baldwin, PhD, of Opthea, shares an update on sozinibercept, a VEGF-C/D inhibitor for the treatment of neovascular age-related macular degeneration.
Sozinibercept, formerly known as OPT-302, is now in a late-stage program in phase 3 clinical development that is looking at the activity of the molecule to improve visual acuity in patients with neovascular AMD.
“We have our ShORe study testing sozinibercept in combination with ranibizumab. That’s well advanced, looking at about 80% recruitment right now.